
usd dec pm et
summari agil diversifi global manufactur life scienc chemic analysi
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
dec pm stock trade
oct-q revenu grew yoy led strong
organ growth yoy crosslab
sale yoy diagnost
genom growth
driven expand market patholog
product nucleic acid solut yet life
scienc appli market lsam
continu drag overal growth
organ revenu yoy oct-q
fy oct
partial explain lsam contract year
china sale total grew around
fy versu fy think
sometim get hit tariff twice
tariff drive cost increas certain
instrument compon sourc abroad
china tariff -made good
reduc price finish product
export china
despit trade issu think overal oper
margin improv fy rapidli
grow highest margin crosslab busi
becom greater mix sale success
cross-sel lab effici solut
lsam custom think crosslab along
rise demand drive ep
growth fy
see crosslab diagnost genom
 lead earn growth
especi applic
genom continu rapidli expand howev
think partial off-set stiff
competit suppli analyt instrument
pharmaceut custom life
scienc appli market lsam segment
-- thu hold also expect neg
impact tariff continu
revenu gener china-bas
buyer import unlik
sever competitor believ
product facil china
despit tariff weigh lsam margin
recent held overal adjust pre-tax
margin roughli flat fy vs
fy margin aid strong
price power crosslab
segment view expect within
high-growth area sequenc
diagnost supplement organ growth
margin
target fy ep estim --
roughli line histor forward price-to-earnings
averag risk view includ soft demand
pharmaceut govern end market
risk assess reflect benefit broad
product line expans geograph coverag
life scienc diagnost genom research lab
suppli market think agil continu benefit
posit suppli on-going expans
biopharmaceut genom applic around
world benefit balanc intens
competit howev continu develop
cutting-edg technolog requir remain relev
maintain price power present
technolog risk obsolesc need
ever-increas invest view
ep estim base cfra oper earn histor
earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview inc provid investor exposur life scienc
diagnost appli chemic market primari product servic includ analyt
instrument softwar servic consum use research laboratori biopharmaceut
firm academ institut govern clinic set well appli set food
chemic product product test
agil variou busi organ three oper segment life scienc appli
market group approxim revenu oper profit agil crosslab group
revenu oper profit diagnost genom group revenu
life scienc appli market group lsam segment develop manufactur provid
instrument relat consum softwar servic enabl custom identifi quantifi
analyz physic biolog properti substanc lsam product categori includ
liquid ga chromatographi use separ molecul liquid ga mixtur determin
quantiti ident molecul present mass spectrometri use analyz chemic base
characterist pattern fragment ion mass result molecul broken apart
spectroscopi techniqu analyz substanc base absorpt emiss
electromagnet radiat laboratori autom robot vacuum technolog cell analysi
tool use studi cell signal pathway gener cell function behavior metabol profil
august agil expand lsam acquisit biotek instrument billion
biotek acquisit expand capabl cell analysi strengthen posit larg
grow immuno-oncolog immunotherapi area
end market lsam includ follow pharmaceut biotechnolog client reli
agil analyt instrument conduct therapeut research discov develop manufactur
pharmaceut academ govern lab not-for-profit organ play
influenti role technolog adopt therapeut develop pharmaceut molecular
diagnost appli market applic includ raw materi analysi qualiti control
oil refin chemic produc environment test air water soil wast sampl
product inspect qualiti control equip food industri
agil crosslab group segment span entir lab extens consum
servic portfolio design improv laboratori effici major portfolio vendor
neutral mean agil servic restock suppli custom regardless instrument
brand solut rang chemistri suppli servic softwar help connect
entir lab mani agil lsam custom also crosslab client think provid
import competit advantag analyt instrument compani lack type
cross-sel capabl view sale relationship incent lab custom across
agil segment make less like switch supplier might lose perk receiv
agil custom one busi
diagnost genom group segment includ genom nucleic acid contract
manufactur research develop patholog companion diagnost reagent partnership
biomolecular analysi busi product categori includ follow patholog
focus clinic solut tissu base cancer diagnost specif protein flow reagent
use vitro diagnost devic companion diagnost product procedur
design partnership pharmaceut firm identifi patient like benefit specif
target therapi target enrich enabl dna research select specif target region
genom sequenc nucleic acid solut provid activ pharmaceut ingredi
contract manufactur arrang use emerg class drug util
oligonucleotid molecul diseas therapi
competit landscap due often high-tech innov natur agil custom
must frequent innov product meet evolv custom need stay competit
fy oct agil spent million revenu research develop
competit market analyt instrument laboratori suppli servic
intens rival compet primarili basi product innov perform reliabl servic
price agil primari competitor includ larg life scienc tool servic firm
shimadzu water corpor
financi trend total revenu grew billion fy oct billion fy agil
adjust pre-tax incom margin improv fy fy fy margin mark
declin fy howev like due part new tariff erect china
sale adjust ep increas fy fy ep
grown materi faster sale past three year help improv margin roughli
billion cumul share repurchas
agil maintain conserv leverag level ebita-to-interest coverag fy
conserv debt level allow firm focu capit alloc balanc strateg acquisit
return cash sharehold spent acquisit total billion fy
million fy dividend share repurchas combin million fy
million fy
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli under-valued usd
bullish sinc septemb technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
neutral fundament outlook
lst sub-industri
next year expect earn growth
remain posit slow sharpli
rate achiev posit
earn growth view
healthi fund public medic research
demand growth emerg market expect
factor balanc slower
biopharmaceut spend growth
neg effect trade tariff
budget nation institut
nih grow rapidli
academ govern lab turn
help drive sale growth mani lst
compani suppli lab nih
fy sep budget grew vs prior
year follow growth
fy fy respect mark
major acceler averag growth
fy fy believ
boost sale lst
sub-industri grew
expect lst firm
continu see strong demand
publicly-fund lab
prolifer advanc health care around
world also continu drive demand
growth lst firm trend
remain particularli strong china
emerg market rapidli grow middl
class gain access advanc health
care drive suppli need new expand
medic research lab facil
estim trend drove growth
lst sub-industri sale
asia-pacif region expect
continu posit long-term driver
contrast strong demand growth
expect publicly-fund client think
biopharmaceut firm moder
 spend growth year ahead
estim total
spend
biopharmaceut compani grew
annual averag expect slow
howev
mani biopharmaceut firm look limit
spend growth off-set recent
revenu headwind patent expir
public scrutini high drug price larg
swath biopharma typic flow
lst firm suppli depart
research tool softwar contract servic
accordingli think slowdown
biopharma growth reduc tailwind
mani lst firm receiv
client group recent year
final recent escal trade tariff
neg impact lst earn
growth view expect
continu analyt
instrument maker lst sub-industri
global suppli chain see
strong oper profit growth
first half brought lower profit
mani busi think shift
relat escal tariff impos
 -china trade
soften demand -made
instrument china rais product
cost instrument maker limit
suppli chain flexibl end sight
current trade disput expect tariff
continu pressur sale growth
oper margin sub-industri
year-to-d septemb
 life scienc tool
servic rose broader
base index
five-year market price perform dec
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
et cfra keep hold opinion share agil
inc keep target fy ep
estim -- long-term averag forward price-to-earnings expect robust demand
growth co life scienc diagnost unit oct-q ep vs
ahead consensu rais fy ep estim
initi finish fiscal year slight acceler sale
growth yoy oct-q july-q growth adj pre-tax
incom oct-q yoy expect anoth year high singl digit revenu
growth fuel strong sale china yoy
oct-q grow invest yoy think margin
improv limit howev reduc invest plant
equip yoy last three quarter think grow
faster histor averag medium-term prospect
alreadi reflect current valuat /colin scarola
et cfra keep hold opinion share agil
keep target price in-lin peer
 forward ep estim jul-q ep vs
ahead estim rais fy oct ep estim
sale foreign exchang benefit rose
-- driven solid demand china pharmaceut chemic
energi end market life scienc appli market sale rose crosslab
rose diagnost genom rose oper margin improv
basi point repres consecut quarter
year-over-year margin improv note tariff like advers
impact margin next quarter encourag steadi improv
sale oper margin see continu benefit agil diversifi
product offer geograph reach america account
sale europ asia pacif /jeffrey loo cfa
analyst research note compani news
et cfra keep hold opinion share inc
lift target fy oct ep
estim -- roughli line histor forward price-to-earnings averag lift
fy ep estim start fy oct-q ep
vs yoy beat consensu oct-q revenu
yoy growth diverg across oper segment largest life
scienc appli market lsam revenu under-perform organ
lsam revenu exclud acquisit drop yoy contrast sharpli
peer like thermo fisher compar segment see strong
demand growth think may experienc greater impact higher
tariff peer co oct-q china revenu declin yoy
compar china growth strong demand crosslab
sale yoy diagnost genom yoy segment off-set
lsam contract remain neutral share due lsam drag
perform /colin scarola
et cfra keep hold opinion share inc
lift target fy oct ep
estim -- roughli line histor forward price-to-earnings averag july-q
ep vs beat consensu primarili higher
expect revenu lift fy ep estim keep fy
july-q revenu yoy exceed
guidanc rang diagnost genom revenu
crosslab saw strong demand quarter grow sale
yoy respect life scienc appli market grew sale
yoy soft china sale howev saw oper incom fall yoy
july-q mark straight drop oper incom life scienc
segment think materi impact trade war despit
quarter strong overal sale growth adjust pre-tax incom flat yoy
oper cost grew faster sale tariff lower margin least
et cfra keep hold opinion share inc
keep target fy oct ep
estim -- roughli line histor forward price-to-earnings averag apr-q ep
vs miss consensu maintain fy fy
ep estim apr-q revenu yoy miss guidanc
rang diagnost genom revenu
crosslab show solid sale growth quarter yoy
respect life scienc drag growth sale
oper incom declin yoy respect weak
pharmaceut end-market consist sever instrument peer
includ also saw sale pharma-focus segment
declin recent quarter think driven intens
competit suppli drug maker research lab despit soft sale growth
grew adjust pre-tax incom per share yoy gross margin improv
et cfra keep hold opinion share inc
keep target fy oct ep
estim -- roughli line histor forward price-to-earnings averag jan-q ep
vs ahead consensu keep fy ep
estim jan-q sale grew yoy led
growth diagnost genom group dgg sale dgg sale
driven strong demand pharma clinic end market agil
crosslab group acg also strong quarter yoy life
scienc appli market group lsag saw sale growth slow
yoy howev prior nine month think slowdown
relat intensifi competit suppli life scienc custom
high-tech instrument competitor thermofish like
gain market share agil recent quarter view base
slower growth rate due intens competit expect revenu growth
fy slow /colin scarola
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
